A growing number of studies have demonstrated a critical role of the IL-33/ST2 axis in rheumatic diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjögren's syndrome (pSS), systemic sclerosis (SSc), psoriatic arthritis (PsA), gout, and ankylosing spondylitis (AS), indicating a promising potential for IL-33/ST2-targeting therapy in rheumatic disease [41]. This evidence concerns the gene IL1RL1 and systemic lupus erythematosus.